SALT LAKE CITY, May 29, 2018 (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (Nasdaq:COOL) today announced it will host a breakfast event in New York City with key opinion leaders (KOLs) to highlight the current treatment options for burns, wounds and skin defects, and the potential for new therapies in the field.
The event will take place on June 25, 2018 at 8 am EDT. Physicians and leaders in the fields of plastic, reconstructive and burn surgery will be discussing treatment options for skin defects ranging from large third-degree burns to acute wounds. Further, members of the Company’s clinical management team will discuss its first product SkinTE™ – a human cellular and tissue-based product derived from a patient’s own skin to regenerate full-thickness, functionally-polarized skin with all its layers (epidermis, dermis and hypodermis) and appendages, including hair follicles and glands – which is intended for the repair, reconstruction, replacement or supplementation of skin tissue.
“We look forward to hearing from leaders in the field, and to sharing updates from the ongoing limited-market release of SkinTE and its growing potential to change the practice of medicine. SkinTE is helping patients heal in a completely different way, and we think it is filling a void that current treatment options cannot address,” said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
The KOL Summit will include presentations from:
- Scott Hultman, MD, MBA, FACS: Professor of Plastic and Reconstructive Surgery at The Johns Hopkins University School of Medicine, Director of The Johns Hopkins Burn Center, Vice Chair of Strategic Development for the Department of Plastic and Reconstructive Surgery, and former chief emeritus of the Division of Plastic and Reconstructive Surgery, the Ethel and James Valone Distinguished Professor of Surgery, and Founder/Director of the Aesthetic, Laser, and Burn Reconstruction Center of the University of North Carolina.
- Mark S. Granick, MD: Professor and Chief of Plastic Surgery in the Department of Surgery at Rutgers New Jersey Medical School, and affiliated with St. Barnabas Medical Center, Newark Beth Israel Medical Center and University Newark Hospital.
- Gerhard S. Mundinger, MD: Director of Plastic Surgery at the Children's Hospital of New Orleans, Assistant Professor of Clinical Surgery and Assistant Professor of Cell Biology and Anatomy at Louisiana State University Health Sciences Center in New Orleans.
- Stephen Morris, MD: Associate Professor of Surgery at the University of Utah, Medical Director of the University of Utah Burn Center, immediate past Director of the University of Utah Trauma Center and President of the Utah State Committee on Trauma and Chair of the Utah State Trauma System Advisory Committee.
Attendees from PolarityTE’s Clinical Management Team:
- Stephen Milner, MD, BDS, DSc, FRCSE, FACS: Chief Clinical Officer at PolarityTE, former Professor of Plastic and Reconstructive Surgery at The Johns Hopkins University School of Medicine, Director of The Johns Hopkins Burn Center and Professor at the Bloomberg School of Public Health.
- Maurice Nahabedian, MD, FACS: Chief Surgical Officer at PolarityTE, Chairman of the 2018 American Society of Plastic Surgeons Annual Meeting, attending plastic surgeon at the National Center for Plastic Surgery in Virginia, former Professor and Section Chief of Plastic Surgery at the MedStar Washington Hospital Center and the Vice Chairman of the Department of Plastic Surgery at the Georgetown University Hospital.
This event is intended for institutional investors, sellside analysts, buyside analysts, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a seat click here.
For those who are unable to attend in person, a live webcast and replay of the event will be accessible on PolarityTE’s website (https://ir.polarityte.com), or by clicking here.
Following the morning session, KOLs and management will host members of the media for a brief presentation and a period of questions and answers.
To attend the follow-up session intended for media, please contact Allison Blum (LifeSci Public Relations) at Allison@lifescipublicrelations.com.
About PolarityTE™
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient’s own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient’s own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient’s own tissue and uses the patient’s own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE’s innovative method is intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing.
About SkinTE™
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products.
SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE use is contraindicated in patients who have suffered autoimmune responses to the auto-transplantation of their own tissues.
SkinTE is regulated by the FDA as an HCT/P solely under Section 361 of the Public Health Service Act and 21 CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not subject to pre-market clearance or approval requirements, but are subject to post-market regulatory requirements.
Forward Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company’s ongoing compliance with the requirements of The NASDAQ Stock Market and the Company’s ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
CONTACT
Investors:
Rich Haerle
ir@PolarityTE.com
(385) 237-2365
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 535-7743
Media:
David Schull
Russo Partners LLC
David.Schull@RussoPartnersLLC.com
(858) 717-2310
Allison Blum
LifeSci Public Relations
Allison@lifescipublicrelations.com